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Summary
Androgen receptors (AR) are ligand-dependent nuclear transcription factors. These are steroid receptors, similar to 
estrogen receptors (ER). They are expressed in numerous cells in the body, with different constructive roles. AR signalling 
can be involved in the development of a variety of human malignant tumors, such as prostate cancer, bladder, liver, salivary 
glands, kidney, lung, melanoma, sarcoma, breast cancer, and many others. The role of AR is most clear and today best ex-
plained in prostate cancer. The mechanism of AR signalling in other human epithelial tumors is still quite unclear and the 
effects are different to entirely opposite in different tumors. In breast cancer, AR are the most commonly expressed recep-
tors, but still with an incompletely clear role, prognostic and predictive significance. The expression of AR in triple-negative 
breast cancer (TNBC) is highly variable. Despite the marked differences in the results of the various analyzes, they appear 
to have a beneficial effect on the prognosis and are potentially the target of antihormone therapy for treatment of TNBC in 
the future.
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STRUCTURE AND FUNCTION  
OF ANDROGEN RECEPTORS
Androgen receptors (AR) are ligand-depen-
dent nuclear transcription factors, which control 
the expression of specific genes and by which 
the action of androgens (testosterone and dihy-
drostestosterone) in the body takes place. They 
belong to the steroid hormone nuclear receptor 
families, along with estrogen (ER), progesterone 
(PR), glucocorticoid (GR), and mineralocorticoid 
receptors (MR). They are expressed in numerous 
cells and tissues and have different roles, such as 
those in the construction and maintenance of 
the sexual, musculoskeletal, circulatory, immune, 
nervous and hematopoietic system.
AR is one polypeptide, consisting of three 
main domains: N - terminal domains for tran-
scription regulation, DNA binding domain (DBD), 
ligand binding domain (LBD) and the hinged re-
gion, which connects DBD and LBD (1,2). AR ac-
tivity occurs through a ligand-dependent tran-
scriptional activation function and a ligand-in-
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dependent transcriptional activation function. 
Ligand-dependent transcriptional activation func-
tions are linked to LBD and differentiate between 
different nuclear hormone steroid receptors. There 
are two ways in which these ligand-dependent 
functions of AR occur. The first form is a DNA-
dependent form of AR activity, called the genom-
ic, classical, or canonical form of AR function. In 
the absence of ligands, AR are found in the cytosol 
of the cell, bound by heat - schock and other chap-
erons. Androgen (ligand) binding induces confor-
mational changes, dissociation of bound cytosolic 
proteins for AR, and transfer of the AR ligand 
complex to the nucleus, where it dimerizes and 
binds to selective ARE (Androgen response ele-
ments) in target genes, which modulate the tran-
scription process. Transcriptional activity of the 
AR - androgen complex is also modulated by spe-
cific protein - co - regulators, which, by binding to 
activated AR, enhance or suppress the transcrip-
tion process. (1,2) Another form of ligand-depen-
dent function of AR is DNA-independent form, 
also called non-genome, non-classical, or non-ca-
nonical form of AR function, whereby alternative 
signaling pathways such as ERK/Akt and MAPK 
are triggered within moments of androgen bind-
ing to the receptor, which is too fast to generate a 
signaling cascade via DBD, by DNA binding, to 
regulate the transcriptional and translational pro-
cesses. In addition, other alternative signaling and 
indirect regulation pathways of transcription and 
translation processes that occur in DNA-indepen-
dent AR binding function have been explored, 
and these mechanisms have been observed in a 
number of different cells, however, studies of this 
mechanism remain at in vitro study, with no clear 
answer as to their exact physiological significance. 
The ligand-independent activities of AR are trig-
gered by a number of different growth factors, 
and through phosphorylation of AR or interaction 
with coactivators, they ultimately affect transcrip-
tion and translation processes.
An example of such an AR mechanism of ac-
tion is the IL - 6 pathway, which activates AR via 
protein kinase A (PKA), protein kinase C (PKC) 
and the MAPK signaling pathway. Such mecha-
nisms have been observed and are of clinical im-
portance in prostate cancer (1,2,3). Glutamine re-
peats (CAGs) occur in the N - terminal transacti-
vation domain (NTD) in the AR composition and 
the number of these repeats is variable, resulting 
in variations in all amino acids in the AR composi-
tion. Shorter glutamine repeats are associated 
with a stronger transcriptional activity of AR, 
which also increases the risk of malignant altera-
tion, which has been observed in men who are 
more likely to have prostate cancer (1-3).
THE ROLE OF ANDROGEN RECEPTORS  
IN HUMAN MALIGNANT TUMORS
AR signalling can be involved in the develop-
ment of a variety of human malignant tumors, 
such as prostate cancer, bladder, liver, salivary 
glands, kidney, lung, melanoma, sarcoma, breast 
cancer, and many others (4). The role of AR in 
prostate cancer is much clearer and better ex-
plained today than AR signaling in other human 
epithelial tumors (3). However, it is known today 
that signaling via steroid receptors is often associ-
ated with the development and progression of the 
disease, in a number of these cancers. The exact 
mechanism by which AR signaling participates in 
the promotion, development, and progression of 
bladder cancer is still unknown, however, sure 
role of AR in carcinogenesis may explain the dif-
ferences observed between men and women with 
urothelial cancer, and they place this tumor in the 
category of hormone-dependent tumors (5).
The expression of AR in most ductal variants 
of salivary gland tumors, which are known to be 
less responsive to chemotherapy, may in the fu-
ture allow the treatment of these tumors with an-
tihormonal therapy (6).
Hepatocellular carcinoma, pancreatic cancer 
and their surrounding tissues to some extent ex-
press AR, and AR itself, not including androgens, 
appears to play a role in the carcinogenesis and 
development of these tumors and make potential-
ly interesting therapeutic targets (7).
The presence of AR in malignant melanoma 
cells supports metastatic potential and affects the 
development of distant metastases (8). On the oth-
er hand, the presence of AR in cells of clear cell or 
papillary kidney cancer seems to be associated 
with better clinical course and prognosis of the 
disease (9).
Differences in the course of the disease and 
the prognosis of lung cancer between men and 
women have suggested the influence of steroid 
hormones and numerous studies have demon-
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strated the effect of ER, PR or AR, although often 
contradictory (10).
Today we still do not have a definitive answer 
about the role of AR in some of the tumors studied, 
the results of the studies conducted so far are often 
contradictory, and more detailed analyzes and 
model work, such as ARKO (AR knock out) mice 
show how AR actually have different effects on dif-
ferent cell lines, even in the same tumor (11).
Further studies are needed to undoubtedly 
define the position of AR in the tumorigenesis, 
metastasizing and prognosis of certain hormone-
dependent malignancies, and the most relevant 
data are currently available in prostate cancer and 
breast cancer (BC).
ANDROGEN RECEPTORS  
IN PROSTATE CANCER
The impact of androgens on the growth and 
survival of prostate cancer cells has long been 
known. Androgen deprivation therapy (ADT) is 
now the backbone of treatment in advanced, and 
also shows success in the treatment of high-risk 
early prostate cancer. Androgens and AR are the 
basic regulators of the cell proliferation-death ra-
tio, on which the continued growth and survival 
of the prostate tumor depends (12).
Activation of various growth-promoting sig-
naling pathways plays a role in the development 
of prostate cancer. Such is also the androgen-de-
pendent up-regulation of transcription factors be-
longing to the ETS family, which happens by fu-
sion of the AR-regulated TMPRSS2 promoter gene 
and the coding region of the ERG and ETV1 genes, 
members of the ETS family. The process is man-
aged by AR, who are thus responsible for tran-
scription, leading to cell cycle progression. The 
described mechanism occurs in about 50% of 
prostate cancer cases (13).
In addition, other signaling pathways are ac-
tive in prostate cancer, such as PI3K and RAS / 
RAF, dysregulation of which has been observed in 
both early and advanced stages of prostate cancer 
(14), but most studies indicate significant altera-
tions in the AR signaling pathway, over all others, 
and therefore this mechanism remains a key regu-
lator of prostate cancer pathogenesis. Therefore 
the rationale to use androgen suppression meth-
ods in the treatment of prostate cancer. Initial treat-
ment is based on the idea of complete androgen 
blockade: conventional ADT is achieved by AR de-
privation by removing testosterone generated in 
the testes, either by surgical or chemical (GnRH 
analogs) orchidectomy, to which therapy with AR 
antagonists/ antiandrogens is often added (15). 
Such androgen blockade is not conclusive and over 
time, castration-resistant prostate cancer (CRPC) 
develops, when the disease no longer responds to 
androgen-deprivation therapy methods.
Several mechanisms have been shown to un-
derpin CRPC development: point mutations of 
AR, amplification of AR, changes in androgen 
 biosynthesis, changes in AR cofactors, variations 
of AR (3). In most cases it happens through AR 
overexpression associated with continuous tumor 
steroidogenesis, binding and activation of AR by 
alternative ligands, such as estrogen and proges-
terone, glucocorticoids and flutamide, by ligand-
independent mechanisms of AR activation by in-
teracting with Akt, HER2 and Ack1 kinases that 
phosphorylate AR and with non-coding RNAs 
that bind to AR to stimulate transcription of target 
genes or, to a lesser extent, AR-independent path-
ways via Stat3 signaling or up-regulation of anti-
apoptotic Bcl-2 (2). The mechanisms described in-
dicate a key role for AR in both the development 
of CRPC and the development of resistance to AR 
directed therapy.
ANDROGEN RECEPTORS  
IN BREAST CANCER
AR are the most commonly expressed hor-
mone receptors in BC and over 70 % of all BC have 
positive AR (16). However, despite decades of re-
search into AR in various BC subtypes, their role 
as an independent predictive and prognostic fac-
tor has not been clearly defined to date, and there-
fore the clinical significance is still incompletely 
understood today. AR are expressed in two types 
of mammary epithelial cells: mostly uniformly 
and diffusely in metaplastic apocrine cells and in 
about 5 to 30 % of normal luminal epithelial cells, 
without apocrine differentiation. They are there-
fore most commonly expressed in the apocrine 
and lobular histological type of breast cancer, and 
are least expressed in the metaplastic, mucinous, 
and medullary types. They are more frequently 
present in luminal, ER positive breast cancers and 
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are strongly correlated with ER and PR, and less 
frequently present in ER negative tumors, among 
which they are more commonly correlated with 
HER2 protein expression (17,18).
Preclinical studies have shown that the effect 
of AR in different BC cell lines can be both stimu-
lating and inhibitory, depending on the presence 
or absence of ER. According to some studies, in an 
ER positive environment, AR is considered a tu-
mor suppressor because it exhibits antiprolifera-
tive effects resulting from the interaction of ER 
and AR signaling pathways, that is, antagonizing 
ER activity by AR, which occurs through competi-
tive ER knockdown and binding to ERE (Estrogen 
esponse elements) and formation of an inactive 
transcription complex, which does not progress to 
further transcription of targeted ER genes.
Androgen-activated AR compete with the ER 
for a limited amount of transcriptional coactiva-
tors, thereby inhibiting target ER genes and acti-
vating target AR genes (19). Expression of AR was 
observed in less aggressive forms of the disease: 
tumors of smaller size, lower grade, lower prolif-
erative index, without affected lymph nodes (20). 
Several different studies and meta-analyzes on the 
role of AR in BC have shown interesting and often 
conflicting results. In some, AR expression in 
breast cancer was positively correlated with dis-
ease - free survival (DFS) and overall survival (OS) 
(16,21), while in others, no statistically significant 
causal relationship was found (22).
Some studies have shown that the expression 
of AR in BC is a positive indicator and correlates 
with DFS and OS in ER positive tumors but not in 
ER negative ones (23,24), while other studies have 
shown that it is precisely in ER negative, that is, in 
TNBC, that the causal correlation between the 
presence of AR and better DFS and OS is the high-
est (25,26). Similar was seen in the studies that 
have shown that the expression of AR has been 
correlated with the molecular subtypes of BC.
The expression of AR in relation to gender 
showed a significant association of AR expression 
with good clinical outcomes in women with BC, 
whereas in men there was no statistical associa-
tion (22). Numerous differences in the results of 
the aforementioned studies are often explained by 
insufficient sample sizes for obtaining statistically 
and clinically relevant data, but also by differenc-
es in the AR evaluation methods used, as well as 
defined limits for AR positivity (16,21-26).
In the sense of predictivity, some studies sug-
gest an association of AR with better response to 
antihormonal therapy, but in response to chemo-
therapy AR positive tumors, regardless of the ex-
pression of other receptors (ER, PR, HER2), ap-
pear to retain luminal tumor behavior and lower 
rates can be expected in the response (27).
AR were recognized as a therapeutic target in 
breast cancer long before the discovery of tamoxi-
fen and aromatase inhibitors, and steroidal andro-
gens were unselectively used in BC therapy until, 
owing to their significant toxic profile (virilization 
and other masculinizing effects), they were re-
placed by the arrival of new endocrine therapies.
The results of preclinical studies show main-
ly antiproliferative effects of androgens on ER and 
AR positive tumor cell lines and indicate that AR 
agonists could be a logical therapeutic choice in 
luminal BC (28).
At the clinical level, as mentioned, there is his-
torical evidence of efficacy over half a century, but 
few controlled clinical studies are available, and it 
is therefore not entirely clear which subtypes 
would best respond to androgens and to what ex-
tent, and what therapeutic combinations, with oth-
er active agents, would be the right ones (29).
Studies with newer non-steroidal selective 
AR modulators (SARMs) and nonsteroidal andro-
gens, such as the phase II study with enobosarm 
(NCT02463032), are underway to answer some of 
these questions.
ANDROGEN RECEPTORS  
IN TRIPLE-NEGATIVE BREAST CANCER
The expression of AR in TNBC, according to 
various studies, is highly variable, but the share of 
about 25-35% of AR positive TNBC is most com-
monly reported (30.) According to the molecular 
classification of TNBC in six subgroups, the LAR 
subtype - luminal AR subtype, characterized by 
AR signaling, was identified, in which the most 
significant AR expression was observed, in terms 
of the highest percentage of AR positive tumor 
cells and staining intensity (31).
According to the immunohistochemical divi-
sion of TNBC into the core - basal subtype (ER-, 
PR-, HER2-, CK5 / 6 + and / or EGFR +) and 5NP 
subtype (all five markers negative) (32), studies 
have shown a higher prevalence of AR in 5NP 
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subtype (33). Also, almost all AR-positive TNBC 
exhibit morphological characteristics in the direc-
tion of apocrine differentiation and, therefore, 
with respect to prognostic and predictive differ-
ences, the need to distribute TNBC to the apocrine 
subtype, which expresses the characteristics of 
ER-positive tumors and nonapocrine, ductal, 
poorly differentiated subtype, is emphasized (18).
A positive correlation between AR expres-
sion and BRCA1 / 2 mutation was also observed 
and BRCA1 was considered a coactivator of the 
AR signaling pathway (34).
Although numerous studies on the role of 
AR in TNBC have been compromised by differ-
ences in methodology and defined cut-off values 
and often of inappropriate sample size, the results 
obtained to date undoubtedly indicate a prognos-
tically favorable effect of AR expression in TNBC 
(35,36).
While some studies have shown that there is 
no statistically significant positive effect of AR on 
survival in TNBC (24), a number of them have 
shown that AR expression in TNBC is an indepen-
dent indicator of better DFS and OS in early TNBC 
(22,37). The expression of AR in TNBC is associ-
ated with better clinicopathological predictive and 
prognostic factors. It is more common in smaller 
tumors, lower grade, lower proliferative index, 
without lymph node involvement, lower clinical 
stage (24,33).
There was generally no difference in AR ex-
pression between early TNBC and metastatic dis-
ease, and if so, there was a trend toward lower AR 
expression in metastatic lesions and disease recur-
rence relative to the primary tumor, which is ex-
plained by the loss of AR expression in the process 
of metastasizing (30,33). It seems that the level of 
intratumoral AR expression is of greater prognos-
tic importance than the mere presence of AR itself: 
a worse prognosis in TNBC with decreased intra-
tumoral AR expression was observed, and vice 
versa, which is explained by suppression of tumor 
cell proliferation by the antiproliferative effect of 
AR stimulation (38). In seeking biomarkers of 
prognostic and predictive value for TNBC, some 
studies have attempted to correlate AR and to find 
common utility in combinations with other mark-
ers, such as EGFR, with which a negative correla-
tion of AR was found (39) and E – cadherin, with 
which AR is positively correlated (40).
The LAR subtype TNBC, that is, the expres-
sion of AR in TNBC, shows poorer rates of pCR on 
neoadjuvant chemotherapy (41). In contrast, they 
show good response to antihormonal therapy and 
so far, several clinical studies have investigated 
the effect of antiandrogen therapy targeting AR-
positive TNBC, such as phase II studies with bi-
calutamide (42) and enzalutamide (43), but also a 
combination with new therapeutic strategies, such 
as PI3K inhibitors, CDK4/6 inhibitors, or mTOR 
inhibitors (44).
CONCLUSION
Androgen receptors are ubiquitiously found 
accross many human malignancies. Somewhat 
clearer is their role in the prostate cancer. They are 
definitely important, in the clinical and therapeu-
tic manner, for the TNBC. According to AR ex-
pression there are probably two different worlds 
of TNBC immunophenotype. It could easily be 
that in the future, setting better correlation be-
tween AR expression and other molecular and 
hystological characteristics of TNBC together, and 
getting to analyze more appropriate cohorts of 
TNBC patients, we find a real therapeutic solution 
for an important cohort of patients.
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Sažetak
ANDROGENSKI RECEPTORI: NEJASAN SVEPRISUTAN MEHANIZAM  
ILI KLJUČ KOJI NEDOSTAJE U TROSTRUKO NEGATIVNOM RAKU DOJKE?
A. Tečić Vuger, R. Šeparović, Lj. Vazdar, M. Pavlović, P. Lepetić, S. Šitić, B. Šarčević and D. Vrbanec
Androgenski receptori (AR) su jezgrini prepisivački čimbenici ovisni o ligandu. To su steroidni receptori, slični estro-
genskim receptorima (ER). Izraženi su u brojnim stanicama s različitim gradivnim ulogama. AR signalizacija može biti 
uključena u razvoj različitih zloćudnih tumora, poput raka prostate, mokraćnog mjehura, jetre, žlijezda slinovnica, bubrega, 
pluća, melanoma, sarkoma, raka dojke i mnogih drugih. Uloga AR najjasnija je i najbolje objašnjena u raku prostate. Meha-
nizam AR signalizacije u drugim humanim epitelnim tumorima još je uvijek nejasan i učinci su kod različitih tumora razli-
čiti, sve do potpuno oprečnih. U raku dojke AR su najčešće izraženi receptori, ali još uvijek s nepotpuno jasnom ulogom, 
prognostičkim i prediktivnim značajem. Izraženost AR u trostruko negativnom raku dojke (TNBC) vrlo je varijabilna. Una-
toč izraženim razlikama u rezultatima različitih analiza, čini se da blagotvorno utječu na prognozu i potencijalna su meta 
antihormonske terapije za liječenje TNRD u budućnosti.
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